X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition complements AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): Ac225-PSMA
Therapeutic Area: Oncology Product Name: FPI-2265
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $2,400.0 million Upfront Cash: $2,000.0 million
Deal Type: Acquisition March 19, 2024
Details:
The license agreement grants Fusion exclusive worldwide rights to develop and commercialize compounds covered by the patent, which includes FPI-2265 for the treatment of prostate-specific membrane antigen-expressing cancers.
Lead Product(s): Ac225-PSMA
Therapeutic Area: Oncology Product Name: FPI-2265
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Heidelberg University
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 16, 2024
Details:
FPI-2265 (Ac225-PSMA) is a targeted alpha therapy (TAT) targeting prostate specific membrane antigen (PSMA). It is under phase 2/3 clinical development for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with progressive disease.
Lead Product(s): Ac225-PSMA
Therapeutic Area: Oncology Product Name: FPI-2265
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Lead Product(s): Actinium-225
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: BWX Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration November 16, 2023
Details:
[225Ac]-FPI-2068 (FPI-2068) is a targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that express EGFR and cMET. EGFR and cMET are validated cancer targets that are co-expressed in multiple tumor types.
Lead Product(s): [225-Actinium]-FPI-2068
Therapeutic Area: Oncology Product Name: FPI-2068
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
FPI-2059 is a small molecule targeted alpha therapy designed to deliver actinium-225 to tumor sites expressing neurotensin receptor 1 (NTSR1), a protein that is overexpressed in gastrointestinal, prostate, pancreatic ductal adenocarcinoma and multiple other cancers.
Lead Product(s): FPI-2059,FPI-2058
Therapeutic Area: Oncology Product Name: FPI-2059
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Through the acquisition of Phase 2 program evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers, strengthens the pipeline of innovative targeted alpha therapies.
Lead Product(s): Ac225-PSMA
Therapeutic Area: Oncology Product Name: Ac225-PSMA
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: RadioMedix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 15, 2023
Details:
[111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide.
Lead Product(s): [225Ac]-FPI-1434
Therapeutic Area: Oncology Product Name: [225Ac]-FPI-1434
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BWX Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
FPI-1966 is a targeted alpha therapy designed to target and deliver an alpha emitting medical isotope, actinium-225, to cancer cells expressing FGFR3; a receptor that is overexpressed on several tumor types, including bladder, ovarian and head and neck cancers.
Lead Product(s): Actinium-225-Vofatamab
Therapeutic Area: Oncology Product Name: [225Ac]-FPI-1966
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
[225Ac]-FPI-2059 (FPI-2059) is a targeted alpha therapy combining actinium-225 with a small molecule designed to target neurotensin receptor 1 (NTSR1), in development as a potential treatment for various solid tumors.
Lead Product(s): 225Ac-IPN-1087
Therapeutic Area: Oncology Product Name: FPI-2059
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
